Last Updated : November 23, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Odefsey | emtricitabine/rilpivirine/ tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
Ofev | Nintedanib | Idiopathic pulmonary fibrosis | List with clinical criteria and/or conditions | Complete | ||
Ogivri | Trastuzumab | Withdrawn | ||||
Olmetec | Olmesartan medoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | ||
Olmetec Plus | Olmesartan medoxomil + hydrochlorothiazide | Hypertension | List in a similar manner to other drugs in class | Complete | ||
Olumiant | baricitinib | Alopecia areata, severe | Reimburse with clinical criteria and/or conditions | Active | ||
Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | ||
Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
Onivyde | Irinotecan Liposome | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete |